Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.
Daniel Yick Chin Heng(University of Calgary), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Pascale Dutailly(Ipsen (France)), Gury K. Doshi(Texas Oncology), Alisha Monnette, Valérie Perrot(Ipsen (France)), Aude Houchard(Ipsen (France)), Yunfei Wang(Central South University), Mickael Löthgren(Ipsen (France))
Cited by 0
Related Papers
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
|Journal of Clinical Oncology|2024|170
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136